SEC 13F manager · CIK 0001103804

Viking Global 13F holdings

Viking Global's latest SEC 13F top holdings and quarterly rebalancing. 13F data is a report-period snapshot, not a live portfolio.

Viking Global's 13F is useful for reading large-cap growth and quality exposure across sectors in a long/short-oriented investment process.

Open dashboard

Watch

What to watch in this manager's 13F

The useful signal is not the holding change alone, but the company question it creates.

-How weights shift between large-cap growth and defensive quality.
-Which filing evidence supports healthcare, technology, and consumer exposure.
-Whether top-position risk is tied to performance, regulation, or cost structure.

Questions

Representative questions

Use these as starting points to move from a 13F signal into company filing research.

01Compare Viking top holdings as growth names versus quality names using filing evidence.
02Summarize regulatory and cost risks for healthcare and technology names Viking increased.
03Check whether reduced names show performance deceleration in filings.
04Assess whether Viking sector shifts look defensive or offensive.

Filing summary

Report period

Mar 31, 2026

13F-HR

Filing date

May 15, 2026

0001103804-26-000004

Top holdings value

$26.3B

30 positions

Top 10 weight

34.91%

Dec 31, 2025

Top holdings

Public 13F information table summary sorted by reported market value.

IssuerMarket valueWeightChange

비자

View company

$1.9B5.35%Increased

TAIWAN SEMICONDUCTOR MANUFAC

874039100

$1.5B4.22%Decreased

찰스 슈왑

SCHW

View company

$1.4B3.86%Increased

월트디즈니

DIS

View company

$1.3B3.59%Increased

FORTIVE CORP

34959J108

$1.2B3.48%Increased

에어 프로덕츠 앤 케미컬스

APD

View company

$1.2B3.33%Decreased

맥도날드

MCD

View company

$1.1B3.15%Increased

쉐윈-윌리엄스

SHW

View company

$997.8M2.79%Decreased

테슬라

TSLA

View company

$927M2.59%Increased

애플

AAPL

View company

$911.9M2.55%New

BRIDGEBIO PHARMA INC

10806X102

$879.4M2.46%Decreased

카바나

CVNA

View company

$874M2.44%Increased

Quarterly rebalancing signals

Weight increases

애플

AAPL

+2.55%

페덱스

FDX

+1.93%

메타

Weight decreases

PNC 파이낸셜 서비스

PNC

-2.27%

에이엠디

AMD

-2.13%

DRAFTKINGS INC NEW

26142V105

-1.75%

마이크로소프트

MSFT

-1.74%

로스 스토어즈

ROST

-1.51%

How to interpret 13F data

Viking's short book and hedges are not visible in 13F, so net exposure is unknown.
Long positions alone should not be treated as the full investment stance.
13F data is published after quarter end, so holdings may have changed.
Short positions, some non-U.S. holdings, and confidential treatment items may not be visible.
KRW Ontology treats 13F as input for follow-up filing research, not as a buy signal.

FAQ

What is this 13F page for?

Use it to see which U.S. listed equities a manager disclosed, then turn those holdings into follow-up company and risk research questions.

Continue with another flow

What to watch in this manager's 13F

The useful signal is not the holding change alone, but the company question it creates.

-How weights shift between large-cap growth and defensive quality.

-Which filing evidence supports healthcare, technology, and consumer exposure.

-Whether top-position risk is tied to performance, regulation, or cost structure.

Representative questions

Use these as starting points to move from a 13F signal into company filing research.

01Compare Viking top holdings as growth names versus quality names using filing evidence.

02Summarize regulatory and cost risks for healthcare and technology names Viking increased.

03Check whether reduced names show performance deceleration in filings.

04Assess whether Viking sector shifts look defensive or offensive.

How to interpret 13F data

Viking's short book and hedges are not visible in 13F, so net exposure is unknown.

Long positions alone should not be treated as the full investment stance.

13F data is published after quarter end, so holdings may have changed.

Short positions, some non-U.S. holdings, and confidential treatment items may not be visible.

KRW Ontology treats 13F as input for follow-up filing research, not as a buy signal.

What to watch in this manager's 13F

The useful signal is not the holding change alone, but the company question it creates.

-How weights shift between large-cap growth and defensive quality.

-Which filing evidence supports healthcare, technology, and consumer exposure.

-Whether top-position risk is tied to performance, regulation, or cost structure.

Representative questions

Use these as starting points to move from a 13F signal into company filing research.

01Compare Viking top holdings as growth names versus quality names using filing evidence.

02Summarize regulatory and cost risks for healthcare and technology names Viking increased.

03Check whether reduced names show performance deceleration in filings.

04Assess whether Viking sector shifts look defensive or offensive.

How to interpret 13F data

Viking's short book and hedges are not visible in 13F, so net exposure is unknown.

Long positions alone should not be treated as the full investment stance.

13F data is published after quarter end, so holdings may have changed.

Short positions, some non-U.S. holdings, and confidential treatment items may not be visible.

KRW Ontology treats 13F as input for follow-up filing research, not as a buy signal.